Lilly Collaborates with OpenAI to Develop Novel Antibiotics Against Drug-Resistant Pathogens

1. Collaboration: Eli Lilly and Company has announced a collaboration with OpenAI to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
2. Antimicrobial Resistance: Antimicrobial resistance (AMR) is a significant public health threat, exacerbated by poverty and inequality, particularly in low- and middle-income countries.
3. Generative AI: The collaboration aims to accelerate the discovery of novel antimicrobials using OpenAI's generative AI, which can develop custom, purpose-built technologies to combat drug-resistant pathogens.
4. Social Impact Venture Capital Portfolio: Lilly has committed $100 million to the AMR Action Fund, aiming to provide patients with two to four new antibiotics by 2030.
5. Industry Trend: Lilly is the latest pharmaceutical company to partner with OpenAI, following Moderna and Sanofi, highlighting OpenAI's growing influence in the pharmaceutical industry.